ClinicalTrials.gg
RecruitingNCT07054346LUTACTUpdated Aug 28, 2026

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

A Phase 1 interventional study of 177 Lutetium Prostate-Specific Membrane Antigen 617 and Actinium-225 Prostate-Specific Membrane Antigen 617 in Prostate Cancer, Prostate Cancer (Diagnosis) and High-risk Prostate Cancer, sponsored by Thomas Hope. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Thomas Hope · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms — 21 open to participants now, 31 under way, 2 of them phase 3. lutetium (¹⁷⁷Lu) vipivotide tetraxetan · Prostatic Neoplasms.

Planned enrollment
23rd of 41
45 · median 49
Started
2025
with 7 others
Phase 1
9 of 41
4 open now
Primary completion
2027-04
later than 11 of 30 live
Registered
35th of 41
by date

Among the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, this one is the 23rd largest by planned enrollment, is one of 8 that started in 2025, is one of 9 in phase 1, reaches primary completion later than 11 of the 30 other live ones, and was the 35th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

21 of the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About lutetium (¹⁷⁷Lu) vipivotide tetraxetan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, or all of them as a file.
02

Study summary

There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of actinium-225 and lutetium-177 radioligand therapies (RLT) in participants with high or very high risk localized or locoregional prostate cancer planning on undergoing a prostatectomy.

Read the detailed description

PRIMARY OBJECTIVES:

  1. Compare the tumor absorbed dose between 177Lu-PSMA-617 and 225Ac-PSMA-617.
  2. Compare the immunologic priming of 177Lu-PSMA-617 and 225Ac-PSMA-617 with controls in prostatectomy specimens.

SECONDARY OBJECTIVES:

  1. Determine the safety and tolerability of neoadjuvant 177Lu-PSMA-617 and 225Ac-PSMA-617 in participants with high or very high-risk prostate cancer planning to undergo radical prostatectomy.
  2. Estimate PSA response for 177Lu-PSMA-617 and 225Ac-PSMA-617 treatment.
  3. Estimate the rate of pathologic response in participants treated with 177Lu-PSMA-617 and 225Ac-PSMA-617.

EXPLORATORY OBJECTIVES:

  1. Determine the relationship between percent cell necrosis and tumor absorbed dose for both 177Lu-PSMA-617 and 225Ac-PSMA-617.
  2. Compare the heterogeneity of cell necrosis for 177Lu-PSMA-617 and 225Ac-PSMA-617.
  3. Compare messenger ribonucleic acid (mRNA) expression profiles of tumor treated with 177Lu-PSMA-617, 225Ac-PSMA-617, and controls.
  4. Compare mRNA expression profiles of tumors in participants who achieve a PSA50 response and those that do not.
  5. Compare mRNA expression profiles of tumors from archival tissue and at time of prostatectomy.
  6. Compare the percent cell necrosis between participants receiving a single cycle of PSMA RLT versus participants receiving two cycles of PSMA RLT.
  7. Compare the change in uptake on PSMA Positron Emission Tomography (PET) to PSA response and percent cell necrosis.
  8. Descriptively evaluate cell necrosis at the tumor margins.
  9. Evaluate changes in peripheral immune activation markers following radioligand therapy.
  10. Compare the kidney absorbed dose (in Gray) between patients receiving 177Lu-PSMA-617 and those receiving 225Ac-PSMA-617, using post-treatment SPECT imaging acquired 7 days after administration of the first dose.
  11. Evaluate feasibility of PET for imaging actinium-225.

OUTLINE:

Participants will be assigned to 1 of 2 cohorts to receive 177Lu-PSMA-617 or 225Ac-PSMA-617. Additional participants undergoing prostatectomy without RLT will be enrolled as a control group. Participants enrolled in the RLT cohorts will receive 1 to 2 cycles of PSMA radioligand therapy up to 6 weeks apart before a scheduled, non-investigational, prostatectomy four weeks after PSMA radioligand therapy. Participants receiving RLT will be followed up for a safety assessment 6 weeks after surgery and for up to 60 months after prostatectomy for long term follow-up. Participants in the prostatectomy only cohort will have safety and long-term follow-up performed as part of clinical care up to 24 months after surgery.

03

Conditions studied

  • Prostate Cancer
  • Prostate Cancer (Diagnosis)
  • High-risk Prostate Cancer
  • Localized Prostate Carcinoma
  • Very High Risk Prostate Carcinoma

Keywords

  • Radioligand Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. confirmed prostate adenocarcinoma.
  3. High-risk disease as defined as meeting 1 or more of the 3 following criteria:

    1. Gleason score of 4+4 disease or higher, Or Gleason 4+3 with large cribriform component (defined as >0.25 mm in short diameter)
    2. Pelvic nodal on PSMA PET.
    3. Extracapsular extension or seminal vesicle invasion on MRI or PSMA PET.
  4. No evidence of distant metastatic disease as determined by PSMA PET. Nodal disease at or below the iliac bifurcation (clinical stage N1) is allowed.
  5. Maximum Standardized Uptake Value (SUVmax) in the primary tumor greater than 10 on PSMA PET using Gallium-68 (68Ga)-PSMA-11 or piflufolastat F 18 (18F-DCFPyL).

    *Note: this applies to treatment cohorts only; there are no SUV requirements for tissue-only cohorts (Control Group).

  6. Target tumor in the prostate measuring greater than 1.0 cm on MRI.
  7. Willing to undergo prostatectomy with or without lymph node dissection, and candidate for prostatectomy as determined by urologic oncology.
  8. (ECOG) performance status ≤ 2 ( ≥ 60%),
  9. Demonstrates adequate organ function as defined below:

    1. ≥100,000/mcL, independent of transfusions or growth factors within 3 months of treatment start.
    2. ≥10 g/dL, independent of transfusions or growth factors within 3 months of treatment start.
    3. (ANC) ≥1,500/microliter (mcL).
    4. (GFR) ≥ 60 mL/min/1.73 m\^2 , calculated using the Cockcroft-Gault equation.
    5. Albumin ≥2.5 g/dL.
    6. (ALT) or aspartate aminotransferase (AST) ≤3.0 x .
    7. Total (TBIL) ≤2 x the institutional upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤3 x ULN is permitted.

      • Note: this applies to treatment cohorts only; there are no requirements for tissue-only cohorts (Control Group)
  10. Ability to understand and the willingness to sign a written document.
  11. Participants must provide consent to comply to recommended radioprotection precautions during study.
  12. Participants must use adequate and not donate sperm while on study drug and for at least 14 weeks after the last study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with other that are expected to alter or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease- free, treatment- free for more than 3 years prior to randomization, or participants with adequately treated non-melanoma skin cancer, superficial bladder cancer are eligible.
  2. Individuals with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the regimen.
  3. Concurrent and serious (as determined by the principal investigator) medical conditions, including, but not limited to class III or IV congestive heart failure, history of congenital prolonged syndrome, uncontrolled infection, known active or C or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation.
  4. Has received prior prostate cancer therapy.

    a. Prior 5-alpha reductase inhibitors (e.g. finasteride, dutasteride) allowed if discontinued at least 3 weeks prior to treatment start.

  5. Has participated in a study of an investigational therapeutic product and received study treatment or used an investigational device within four weeks of the first dose of treatment.
  6. Prior external beam radiation therapy (EBRT) to the prostate or prostate bed.
  7. Dry mouth that impacts the eating of food (i.e., requiring fluids prior to eating)

Additional exclusion criteria applicable only to participants undergoing intraarterial administration of PSMA RLT:

  1. Severe allergy to iodinated contrast.
  2. Severe atherosclerosis from prior CT imaging study, or greater than 10 pack-year smoking history if no prior imaging available.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (177Lu-PSMA-617)

    Five participants will receive a single dose of 177Lu-PSMA-617 radioligand therapy intravenously (IV), five participants will receive a single dose of 177Lu-PSMA-617 intra-arterially (IA), and five participants will receive two doses over 6 weeks intravenously. In participants receiving two doses, the dose will be divided so that the cumulative dose will be equivalent to participants receiving a single dose. All participants will undergo prostatectomy four weeks after completing radioligand therapy and will be followed up 6 weeks after surgery for safety assessments and at 3, 6, 12, 36, 48, and 60 months for long-term outcomes.

    Drug: 177 Lutetium Prostate-Specific Membrane Antigen 617 · Procedure: Non-investigational, Prostatectomy · Procedure: Prostate Tissue Collection · Procedure: Single-photon emission computed tomography (SPECT)/Computerized tomography (CT) · Procedure: Blood Sample Collection

  • Experimental
    Cohort 2 (225Ac-PSMA-617)

    Five participants will receive a single dose of 225Ac-PSMA-617 radioligand therapy IV, five participants will receive a single dose of 225Ac-PSMA-617 IA, and five participants will receive two doses over 6 weeks IV. In participants receiving two doses, the dose will be divided so that the cumulative dose will be equivalent to participants receiving a single dose. All participants will undergo prostatectomy four weeks after completing radioligand therapy and will be followed up 6 weeks after surgery for safety assessments and at 3, 6, 12, 36, 48, and 60 months for long-term outcomes.

    Drug: Actinium-225 Prostate-Specific Membrane Antigen 617 · Procedure: Non-investigational, Prostatectomy · Procedure: Prostate Tissue Collection · Procedure: Single-photon emission computed tomography (SPECT)/Computerized tomography (CT) · Procedure: Blood Sample Collection

  • Other
    Control Group (Prostatectomy only)

    Participants will obtain a non-investigational prostatectomy. Tumor tissue obtained at the time of surgery will be utilized for comparisons with the cohorts receiving study therapies. All participants will undergo prostatectomy four weeks after completing radioligand therapy and will be followed up 6 weeks after surgery for safety assessments and up to 24 months after surgery.

    Procedure: Non-investigational, Prostatectomy · Procedure: Prostate Tissue Collection · Procedure: Blood Sample Collection

Interventions

  • DrugLutetium (¹⁷⁷Lu) vipivotide tetraxetanStudies of Lutetium (¹⁷⁷Lu) vipivotide tetraxetanLutetium (¹⁷⁷Lu) vipivotide tetraxetan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given intravenously (IV) or intra-arterially (IA)

    Also known as: 177Lu-PSMA-617, Pluvicto, lutetium Lu 177 vipivotide tetraxetan

  • DrugActinium-225 Prostate-Specific Membrane Antigen 617

    Given IV or IA

    Also known as: 225Ac-PSMA-617, Radioligand 225Ac-PSMA-617

  • ProcedureNon-investigational, Prostatectomy

    Undergo non-investigational surgical procedure to remove prostate.

    Also known as: Prostatectomy

  • ProcedureProstate Tissue Collection

    Whole prostate tissue will be collected for correlative research at time of prostatectomy.

    Also known as: Biospecimen Collection

  • ProcedureSingle-photon emission computed tomography (SPECT)/Computerized tomography (CT)

    Imaging procedure

    Also known as: SPECT/CT

  • ProcedureBlood Sample Collection

    Blood samples will be obtained for research purposes

    Also known as: Blood Specimen

06

What researchers measure

Primary outcomes

  1. Mean of tumor absorbed dose (Cohorts 1 and 2)

    The mean tumor absorbed dose on post-treatment SPECT imaging within 7 days of the first radioligand treatment (RLT) will be obtained by using MIM Software to measure absorbed dose and researchers will manually segment activity in the dominant prostate tumor while carefully excluding any activity within the bladder using a threshold of 5 Gray. Using this segmented volume, the mean dose within the tumor in Gray for each participant and standard deviation will be calculated and reported descriptively for Cohorts 1 and 2. A two-sample t-test comparing the dose between Cohort 1 and Cohort 2 and Analysis of Variance (ANOVA) model to compare the dose between different treatment/fractionation modalities within each cohort will be performed.

    Time frame: 1 week

  2. Rate of Cluster of differentiation 3 positive (CD3+) T cell infiltration

    Immunohistochemistry will be performed using standard methods, and stained slides will be scanned using an automated microscope scanner. Five randomly selected fields (0.25 mm\^2) from each participant's primary tumor will be captured. Using color-specific algorithms, CD3+ cell counts will be determined, and the mean of each of the five quantified fields will be used. We will use a two-sample t-test or ANOVA model comparing the CD3+ cell counts between Cohort 1 and Cohort 2 with participants who have not undergone prostatectomy enrolled in the biospecimen protocol, respectively.

    Time frame: 1 day, at time of prostatectomy

Secondary outcomes

  1. Proportion of participants with reported treatment-emergent adverse events (Cohorts 1 and 2)

    The proportion of participants with treatment-emergent adverse events, as classified by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (NCI CTCAE v5.0) will be reported for participants receiving RLT.

    Time frame: Up to 6 weeks after last PSMA RLT administration

  2. Proportion of participants with perioperative complications

    The Clavien-Dindo classification is a widely used system for grading and classifying surgical complications. The Proportion of participants with documented perioperative complications following prostatectomy per the Clavien-Dindo classification will be reported.

    Time frame: Up to 6 weeks after prostatectomy

  3. Median scores on the xerostomia-quality-of-life-scale (XeQoLS)

    The XeQoLS questionnaire measures the effects of salivary gland dysfunction and xerostomia on the four major domains of oral health-related quality of life: physical, pain, personal, and social. The questionnaire consists of 15 items, each rated on a 0-to-4 point Likert scale, with higher scores indicating more severe symptom burden. Median scores for each domain and global score and interquartile ranges will be reported.

    Time frame: Up to 12 months after prostatectomy

  4. Proportion of participants with 50% decrease in level of prostate specific antigen (PSA50)

    The proportion of participants who achieve a greater than 50% decline from baseline PSA drawn prior to Cycle 1 Day 1 (C1D1), up to the day of prostatectomy, will be descriptively reported along with 95% binomial confidence interval. It will be compared between the two treatment Cohorts using a Fischer's test.

    Time frame: Up to 8 weeks

  5. Proportion of participants with complete pathologic response

    Using the prostatectomy specimen, a board certified pathologies will determine pathologic complete response for each participant at time of prostatectomy. The pathologic response to the treatment in the prostate will be evaluated by percentage (0%, \<10%, 10-25%, 50-75%, 75-100%) of viable tumor in the formalin-fixed paraffin embedded specimen. Complete pathologic response will be defined as no viable tumor (0%), and minimal residual disease will be defined as \<10% of viable tumor. The number of participants in Cohorts 1 and 2 with complete pathologic response or minimal residual disease will be counted and the number of participants between the two cohorts will be compared using a Fisher's exact test. The proportion of complete pathologic response and minimal residual disease will be descriptively reported along with 95% binomial confidence interval.

    Time frame: 1 day, at time of prostatectomy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data may be shared with study collaborators during the course of the study.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.

Of 243 non-industry phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's planned 21 months is below that.

Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2025
First posted
Jul 8, 2025
StartActual
Jul 8, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2028
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07054346
Lead sponsor
Thomas Hope
Collaborators
Novartis
Responsible party
Thomas Hope (Professor In Residence, University of California, San Francisco) — Sponsor-investigator
First posted
Jul 8, 2025
Start date
Jul 8, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Aug 28, 2026

Study contacts

Maya Aslam
Contact
Maya.Aslam@ucsf.edu
(415) 514-8987
Thomas A Hope, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium (¹⁷⁷Lu) vipivotide tetraxetan

Start the discussion